{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:49:44Z","timestamp":1766414984923,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Fondazione Cassa Galeno"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-025-01338-w","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T02:24:01Z","timestamp":1737685441000},"page":"427-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of Systemic Anti-psoriatic Drugs in Psoriasis\u00a0Patients with Concurrent\u00a0Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-6505","authenticated-orcid":false,"given":"Giovanni","family":"Damiani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Pacifico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Trigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"1338_CR1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2100219","author":"WH Boehncke","year":"2022","unstructured":"Boehncke WH, Brembilla NC. Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opin Biol Ther. 2022. https:\/\/doi.org\/10.1080\/14712598.2022.2100219.","journal-title":"Expert Opin Biol Ther"},{"key":"1338_CR2","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8:743180.","journal-title":"Front Med (Lausanne)"},{"key":"1338_CR3","volume":"13","author":"A Saalbach","year":"2022","unstructured":"Saalbach A, Kunz M. Impact of chronic inflammation in psoriasis on bone metabolism. Front Immunol. 2022;13:925503.","journal-title":"Front Immunol"},{"issue":"6","key":"1338_CR4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jid.2019.07.727","volume":"140","author":"D Seth","year":"2020","unstructured":"Seth D, Ehlert AN, Golden JB, et al. Interaction of resistin and systolic blood pressure in psoriasis severity. J Invest Dermatol. 2020;140(6):1279-1282.e1.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1338_CR5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/jcm9010186","volume":"9","author":"RR Conic","year":"2020","unstructured":"Conic RR, Damiani G, Schrom KP, et al. Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume. J Clin Med. 2020;9(1):186.","journal-title":"J Clin Med"},{"key":"1338_CR6","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.795055","volume":"13","author":"P \u0141akuta","year":"2022","unstructured":"\u0141akuta P. A factorial randomized controlled trial of implementation-intention-based self-affirmation interventions: findings on depression, anxiety, and well-being in adults with psoriasis. Front Psychiatry. 2022;13: 795055.","journal-title":"Front Psychiatry"},{"key":"1338_CR7","first-page":"151","volume":"11","author":"DMW Balak","year":"2021","unstructured":"Balak DMW, Piaserico S, Kasujee I. Non-alcoholic fatty liver disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies. Psoriasis (Auckl). 2021;11:151\u201368.","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"1338_CR8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-4362.1990.tb03821.x","volume":"29","author":"AS Boyd","year":"1990","unstructured":"Boyd AS, Neldner KH. The isomorphic response of Koebner. Int J Dermatol. 1990;29(6):401\u201310.","journal-title":"Int J Dermatol"},{"issue":"7","key":"1338_CR9","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jdv.15539","volume":"33","author":"G Damiani","year":"2019","unstructured":"Damiani G, Cazzaniga S, Conic RR, Naldi L, Psocare Registry Network. Pruritus characteristics in a large Italian cohort of psoriatic patients. J Eur Acad Dermatol Venereol. 2019;33(7):1316\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1338_CR10","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/pds.5132","volume":"29","author":"C Srinivas","year":"2020","unstructured":"Srinivas C, Odsbu I, Linder M. Risk of common infections among individuals with psoriasis in Sweden: a nationwide cohort study comparing secukinumab to ustekinumab. Pharmacoepidemiol Drug Saf. 2020;29(12):1562\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1338_CR11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaad.2019.07.028","volume":"82","author":"A Sahuquillo-Torralba","year":"2020","unstructured":"Sahuquillo-Torralba A, Carretero G, Rivera R, et al. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: a prospective cohort study. J Am Acad Dermatol. 2020;82(3):738\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1338_CR12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.pmr.2007.02.001","volume":"18","author":"SP Burns","year":"2007","unstructured":"Burns SP. Acute respiratory infections in persons with spinal cord injury. Phys Med Rehabil Clin N Am. 2007;18(2):203\u201316 (v-vi).","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"6","key":"1338_CR13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/sc.2016.173","volume":"55","author":"LY Garcia-Arguello","year":"2017","unstructured":"Garcia-Arguello LY, O\u2019Horo JC, Farrell A, et al. Infections in the spinal cord-injured population: a systematic review. Spinal Cord. 2017;55(6):526\u201334.","journal-title":"Spinal Cord"},{"issue":"2","key":"1338_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1310\/sci1802-187","volume":"18","author":"LU Edokpolo","year":"2012","unstructured":"Edokpolo LU, Stavris KB, Foster HE Jr. Intermittent catheterization and recurrent urinary tract infection in spinal cord injury. Top Spinal Cord Inj Rehabil. 2012;18(2):187\u201392.","journal-title":"Top Spinal Cord Inj Rehabil"},{"issue":"4","key":"1338_CR15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica. 1978;157(4):238\u201344.","journal-title":"Dermatologica"},{"key":"1338_CR16","doi-asserted-by":"crossref","first-page":"204062231986480","DOI":"10.1177\/2040622319864805","volume":"10","author":"H Kocic","year":"2019","unstructured":"Kocic H, Damiani G, Stamenkovic B, et al. Dietary compounds as potential modulators of microRNA expression in psoriasis. Ther Adv Chronic Dis. 2019;10:2040622319864805.","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"1338_CR17","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.12998\/wjcc.v8.i6.1002","volume":"8","author":"G Damiani","year":"2020","unstructured":"Damiani G, Bragazzi NL, McCormick TS, et al. Gut microbiota and nutrient interactions with skin in psoriasis: a comprehensive review of animal and human studies. World J Clin Cases. 2020;8(6):1002\u201312.","journal-title":"World J Clin Cases"},{"issue":"9","key":"1338_CR18","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.3390\/nu13092934","volume":"13","author":"A Pacifico","year":"2021","unstructured":"Pacifico A, Conic RRZ, Cristaudo A, et al. Diet-related phototoxic reactions in psoriatic patients undergoing phototherapy: results from a multicenter prospective study. Nutrients. 2021;13(9):2934.","journal-title":"Nutrients"},{"issue":"6","key":"1338_CR19","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/jcm8060770","volume":"8","author":"G Damiani","year":"2019","unstructured":"Damiani G, Pacifico A, Russo F, et al. Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study. J Clin Med. 2019;8(6):770.","journal-title":"J Clin Med"},{"issue":"5","key":"1338_CR20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jamadermatol.2022.0434","volume":"158","author":"AM van Huizen","year":"2022","unstructured":"van Huizen AM, Menting SP, Gyulai R, et al. International eDelphi study to reach consensus on the methotrexate dosing regimen in patients with psoriasis. JAMA Dermatol. 2022;158(5):561\u201372.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1338_CR21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","volume":"35","author":"A Nast","year":"2021","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281\u2013317.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1338_CR22","volume":"12","author":"K Reich","year":"2022","unstructured":"Reich K, Kristensen LE, Smith SD, et al. Efficacy and safety of Ixekizumab versus adalimumab in biologic-na\u00efve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial. Dermatol Pract Concept. 2022;12(2):e2022104.","journal-title":"Dermatol Pract Concept"},{"issue":"5","key":"1338_CR23","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15088","volume":"34","author":"A Conti","year":"2021","unstructured":"Conti A, Damiani G, Ruggeri R, et al. Switching infliximab in psoriatic patients during COVID-19 pandemics: a real-life retrospective study comparing intra-versus interclass switching strategies. Dermatol Ther. 2021;34(5):e15088.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1338_CR24","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12793","volume":"32","author":"G Damiani","year":"2019","unstructured":"Damiani G, Conic RRZ, de Vita V, et al. When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatol Ther. 2019;32(2):e12793.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1338_CR25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/ph15010095","volume":"15","author":"G Damiani","year":"2022","unstructured":"Damiani G, Odorici G, Pacifico A, et al. Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter real-life study in a cohort of italian psoriatic patients that avoided secukinumab switching. Pharmaceuticals (Basel). 2022;15(1):95.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1338_CR26","first-page":"469","volume":"27","author":"GH Ibrahim","year":"2009","unstructured":"Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27:469\u201374.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"1338_CR27","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1338_CR28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/10790268.2006.11753855","volume":"29","author":"D Graves","year":"2006","unstructured":"Graves D, Frankiewicz RG, Donovan WH. Construct validity and dimensional structure of the ASIA motor scale. J Spinal Cord Med. 2006;29(1):39\u201345.","journal-title":"J Spinal Cord Med"},{"issue":"1","key":"1338_CR29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13690-022-00891-6","volume":"80","author":"JA Haagsma","year":"2022","unstructured":"Haagsma JA, Charalampous P, Ariani F, et al. The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. Arch Public Health. 2022;80(1):142.","journal-title":"Arch Public Health"},{"key":"1338_CR30","volume":"376","author":"GBD 2019 Ageing Collaborators","year":"2022","unstructured":"GBD 2019 Ageing Collaborators. Global, regional, and national burden of diseases and injuries for adults 70\u00a0years and older: systematic analysis for the Global Burden of Disease 2019 Study. BMJ. 2022;376:e068208.","journal-title":"BMJ"},{"issue":"Supp 1","key":"1338_CR31","doi-asserted-by":"crossref","first-page":"i96","DOI":"10.1136\/injuryprev-2019-043494","volume":"26","author":"SL James","year":"2020","unstructured":"James SL, Castle CD, Dingels ZV, et al. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. Inj Prev. 2020;26(Supp 1):i96\u2013114.","journal-title":"Inj Prev"},{"issue":"10","key":"1338_CR32","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s10067-020-05050-2","volume":"39","author":"G Damiani","year":"2020","unstructured":"Damiani G, Pacifico A, Rizzi M, et al. Patients with psoriatic arthritis have higher levels of FeNO than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement. Clin Rheumatol. 2020;39(10):2981\u20138.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1338_CR33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/bjd.14546","volume":"175","author":"G Damiani","year":"2016","unstructured":"Damiani G, Radaeli A, Olivini A, Calvara-Pinton P, Malerba M. Increased airway inflammation in patients with psoriasis. Br J Dermatol. 2016;175(4):797\u20139.","journal-title":"Br J Dermatol"},{"issue":"2018","key":"1338_CR34","first-page":"3140682","volume":"23","author":"P Santus","year":"2018","unstructured":"Santus P, Rizzi M, Radovanovic D, et al. Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. Biomed Res Int. 2018;23(2018):3140682.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1338_CR35","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaad.2020.05.035","volume":"83","author":"MT Wan","year":"2020","unstructured":"Wan MT, Shin DB, Winthrop KL, Gelfand JM. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: a meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(2):677\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1338_CR36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaci.2020.10.032","volume":"147","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Piaserico S, Naldi L, et al. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience. J Allergy Clin Immunol. 2021;147(2):558-560.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1338_CR37","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13475","volume":"33","author":"G Damiani","year":"2020","unstructured":"Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;33(5):e13475.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1338_CR38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40257-021-00605-8","volume":"22","author":"K Kridin","year":"2021","unstructured":"Kridin K, Schonmann Y, Tzur Bitan D, et al. Coronavirus disease 2019 (COVID-19)-associated hospitalization and mortality in patients with psoriasis: a population-based study. Am J Clin Dermatol. 2021;22(5):709\u201318.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1338_CR39","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15003","volume":"34","author":"K Kridin","year":"2021","unstructured":"Kridin K, Schonmann Y, Damiani G, et al. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis\u2014a population-based cohort study. Dermatol Ther. 2021;34(4):e15003.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1338_CR40","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1080\/09546634.2021.1905766","volume":"33","author":"K Kridin","year":"2022","unstructured":"Kridin K, Schonmann Y, Solomon A, et al. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors. J Dermatolog Treat. 2022;33(4):2014\u201320.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1338_CR41","volume":"33","author":"D Shu","year":"2020","unstructured":"Shu D, Zhang Z, Zhou EY, Ma X, Zhao Y. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study. Dermatol Ther. 2020;33(6):e14512.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1338_CR42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","volume":"25","author":"T Torres","year":"2024","unstructured":"Torres T, Chiricozzi A, Puig L, et al. Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study. Am J Clin Dermatol. 2024;25(2):333\u201342.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1338_CR43","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/cod.13683","volume":"83","author":"A Cristaudo","year":"2020","unstructured":"Cristaudo A, Pigliacelli F, Pacifico A, et al. Teledermatology and hygiene practices during the COVID-19 pandemic. Contact Dermatitis. 2020;83(6):536.","journal-title":"Contact Dermatitis"},{"issue":"4","key":"1338_CR44","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13508","volume":"33","author":"NL Bragazzi","year":"2020","unstructured":"Bragazzi NL, Ricc\u00f2 M, Pacifico A, et al. COVID-19 knowledge prevents biologics discontinuation: data from an Italian multicenter survey during RED-ZONE declaration. Dermatol Ther. 2020;33(4):e13508.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1338_CR45","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqac003","volume":"3","author":"F Balloux","year":"2022","unstructured":"Balloux F, Tan C, Swadling L, et al. The past, current and future epidemiological dynamic of SARS-CoV-2. Oxf Open Immunol. 2022;3(1):iqac003.","journal-title":"Oxf Open Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01338-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:10:44Z","timestamp":1739837444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01338-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01338-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alessia Pacifico, Stefano Ricciardi, Valeria Corazza, David Trigos, Marco Fiore, Claudio Guarneri reported no conflict of interests relevant for the manuscript. Giovanni Damiani is an Editorial Board Member of Dermatology and Therapy. Giovanni Damiani was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol is in line with the principles of Helsinki declaration of 1975 (), revised in 2013. The present study received the approval by the Institutional Review Board of San Raphael Hospital (protocol code 178\/INT\/2021, date of approval 10 November 2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}